Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track AVXL with free AI briefings, catalyst countdowns, and dilution alerts.

AVXL · Anavex Life Sciences Corp.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$118.3M Cash on Hand
52.4mo Cash Runway
Follow AVXL by email Get an email when AVXL reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about AVXL, unsubscribe in one click. Privacy

📣 What AVXL Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Blarcamesine Alzheimer Disease Phase 2/3 · NCT04314934 Completed
ANAVEX2-73 Alzheimer Disease Phase 2/3 · NCT03790709 Completed
Mid dose ANAVEX2-73 Alzheimer Disease Phase 2/3 · NCT03790709 Completed
ANAVEX3-71 Schizophrenia Phase 2 · NCT06245213 Active not recruiting
Ketamine Healthy Early Phase 1 · NCT04928703 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

AVXL holds $118.3M in cash and short-term investments (as of Jun 30, 2026) and burns about $6.8M/quarter from operations, an estimated runway of 52.4 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 25 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AVXL files for a raise →

👥 Who Owns AVXL

Insiders 1.7% Institutions (229 holders) 41.5% Public and other holders 56.8%
HolderTypeShares% of sharesAs of
Vanguard Capital Management Institution (13G, 5%+) 4,663,459 5.03% 2026-06-30
Christopher U Missling
President and CEO, Director · +1.04M options
Insider 1,510,165 1.63% 2025-09-11
Steffen Thomas
Director · +100,000 options
Insider 43,651 0.05% 2025-06-05
Peter D.O. Donhauser
Director · +150,000 options
Insider 5,000 0.01% 2024-06-14

Share count 92,696,842 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full AVXL picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AVXL and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.